nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.622	1	CbGbCtD
Phenylpropanolamine—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.0131	0.0842	CcSEcCtD
Phenylpropanolamine—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.0131	0.0842	CcSEcCtD
Phenylpropanolamine—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0753	CcSEcCtD
Phenylpropanolamine—DRD1—nerve—amyotrophic lateral sclerosis	0.0112	0.087	CbGeAlD
Phenylpropanolamine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0646	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00989	0.0634	CcSEcCtD
Phenylpropanolamine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.00899	0.0699	CbGeAlD
Phenylpropanolamine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00849	0.0545	CcSEcCtD
Phenylpropanolamine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00725	0.0564	CbGeAlD
Phenylpropanolamine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00701	0.0449	CcSEcCtD
Phenylpropanolamine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00682	0.0438	CcSEcCtD
Phenylpropanolamine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00675	0.0433	CcSEcCtD
Phenylpropanolamine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.00673	0.0523	CbGeAlD
Phenylpropanolamine—MAOA—nerve—amyotrophic lateral sclerosis	0.00668	0.0519	CbGeAlD
Phenylpropanolamine—ADRA2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00657	0.0511	CbGeAlD
Phenylpropanolamine—ADRA1A—hindbrain—amyotrophic lateral sclerosis	0.00505	0.0393	CbGeAlD
Phenylpropanolamine—MAOA—hindbrain—amyotrophic lateral sclerosis	0.005	0.0389	CbGeAlD
Phenylpropanolamine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00494	0.0317	CcSEcCtD
Phenylpropanolamine—DRD1—brainstem—amyotrophic lateral sclerosis	0.0048	0.0373	CbGeAlD
Phenylpropanolamine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00444	0.0284	CcSEcCtD
Phenylpropanolamine—Tension—Riluzole—amyotrophic lateral sclerosis	0.00424	0.0272	CcSEcCtD
Phenylpropanolamine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.0042	0.0269	CcSEcCtD
Phenylpropanolamine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00405	0.026	CcSEcCtD
Phenylpropanolamine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00397	0.0255	CcSEcCtD
Phenylpropanolamine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00386	0.03	CbGeAlD
Phenylpropanolamine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00367	0.0235	CcSEcCtD
Phenylpropanolamine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00356	0.0228	CcSEcCtD
Phenylpropanolamine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00344	0.0221	CcSEcCtD
Phenylpropanolamine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.0033	0.0211	CcSEcCtD
Phenylpropanolamine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00319	0.0205	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00314	0.0202	CcSEcCtD
Phenylpropanolamine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00314	0.0201	CcSEcCtD
Phenylpropanolamine—MAOA—embryo—amyotrophic lateral sclerosis	0.00313	0.0243	CbGeAlD
Phenylpropanolamine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00311	0.0242	CbGeAlD
Phenylpropanolamine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00302	0.0193	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00291	0.0186	CcSEcCtD
Phenylpropanolamine—ADRA1A—brainstem—amyotrophic lateral sclerosis	0.00289	0.0225	CbGeAlD
Phenylpropanolamine—MAOA—brainstem—amyotrophic lateral sclerosis	0.00287	0.0223	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.0026	0.0167	CcSEcCtD
Phenylpropanolamine—DRD1—nervous system—amyotrophic lateral sclerosis	0.00252	0.0196	CbGeAlD
Phenylpropanolamine—DRD1—central nervous system—amyotrophic lateral sclerosis	0.00242	0.0188	CbGeAlD
Phenylpropanolamine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.0024	0.0187	CbGeAlD
Phenylpropanolamine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00233	0.015	CcSEcCtD
Phenylpropanolamine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00224	0.0144	CcSEcCtD
Phenylpropanolamine—Rash—Riluzole—amyotrophic lateral sclerosis	0.00222	0.0143	CcSEcCtD
Phenylpropanolamine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00222	0.0142	CcSEcCtD
Phenylpropanolamine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00217	0.0169	CbGeAlD
Phenylpropanolamine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.0021	0.0134	CcSEcCtD
Phenylpropanolamine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00202	0.0157	CbGeAlD
Phenylpropanolamine—MAOA—medulla oblongata—amyotrophic lateral sclerosis	0.002	0.0155	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00195	0.0151	CbGeAlD
Phenylpropanolamine—DRD1—brain—amyotrophic lateral sclerosis	0.00192	0.0149	CbGeAlD
Phenylpropanolamine—ADRB1—nervous system—amyotrophic lateral sclerosis	0.00192	0.0149	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.0019	0.0148	CbGeAlD
Phenylpropanolamine—ADRB1—central nervous system—amyotrophic lateral sclerosis	0.00185	0.0144	CbGeAlD
Phenylpropanolamine—MAOA—spinal cord—amyotrophic lateral sclerosis	0.00178	0.0139	CbGeAlD
Phenylpropanolamine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00163	0.0127	CbGeAlD
Phenylpropanolamine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00157	0.0122	CbGeAlD
Phenylpropanolamine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00154	0.012	CbGeAlD
Phenylpropanolamine—ADRA2A—medulla oblongata—amyotrophic lateral sclerosis	0.00153	0.0119	CbGeAlD
Phenylpropanolamine—ADRA1A—nervous system—amyotrophic lateral sclerosis	0.00152	0.0118	CbGeAlD
Phenylpropanolamine—MAOA—nervous system—amyotrophic lateral sclerosis	0.0015	0.0117	CbGeAlD
Phenylpropanolamine—ADRB1—brain—amyotrophic lateral sclerosis	0.00147	0.0114	CbGeAlD
Phenylpropanolamine—ADRA1A—central nervous system—amyotrophic lateral sclerosis	0.00146	0.0113	CbGeAlD
Phenylpropanolamine—MAOA—central nervous system—amyotrophic lateral sclerosis	0.00145	0.0112	CbGeAlD
Phenylpropanolamine—ADRA1A—cerebellum—amyotrophic lateral sclerosis	0.00143	0.0111	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—amyotrophic lateral sclerosis	0.00141	0.011	CbGeAlD
Phenylpropanolamine—ADRA2A—spinal cord—amyotrophic lateral sclerosis	0.00137	0.0106	CbGeAlD
Phenylpropanolamine—SLC6A2—brain—amyotrophic lateral sclerosis	0.00125	0.00969	CbGeAlD
Phenylpropanolamine—ADRA1A—brain—amyotrophic lateral sclerosis	0.00116	0.00901	CbGeAlD
Phenylpropanolamine—ADRA2A—nervous system—amyotrophic lateral sclerosis	0.00115	0.00896	CbGeAlD
Phenylpropanolamine—MAOA—brain—amyotrophic lateral sclerosis	0.00115	0.00893	CbGeAlD
Phenylpropanolamine—ADRA2A—central nervous system—amyotrophic lateral sclerosis	0.00111	0.00863	CbGeAlD
Phenylpropanolamine—ADRA2A—cerebellum—amyotrophic lateral sclerosis	0.00108	0.00843	CbGeAlD
Phenylpropanolamine—ADRA2A—brain—amyotrophic lateral sclerosis	0.000881	0.00685	CbGeAlD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	0.000435	0.00466	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000434	0.00465	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Parkinsons Disease Pathway—CASP3—amyotrophic lateral sclerosis	0.000424	0.00455	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000422	0.00452	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000417	0.00447	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000415	0.00444	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000406	0.00435	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000398	0.00427	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000392	0.0042	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000389	0.00417	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	0.000388	0.00416	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000386	0.00413	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000384	0.00412	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000369	0.00396	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000365	0.00391	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000359	0.00384	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000359	0.00384	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000359	0.00384	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000355	0.0038	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000353	0.00378	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000339	0.00364	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000333	0.00357	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000333	0.00357	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000329	0.00352	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000329	0.00352	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000327	0.00351	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000323	0.00347	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.00032	0.00343	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000314	0.00337	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000301	0.00322	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000297	0.00318	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000295	0.00317	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000291	0.00312	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000284	0.00305	CbGpPWpGaD
Phenylpropanolamine—MAOA—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000284	0.00304	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000275	0.00295	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000272	0.00291	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000258	0.00277	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000246	0.00264	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000238	0.00255	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000235	0.00252	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000234	0.00251	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000221	0.00237	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000219	0.00234	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000217	0.00233	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000217	0.00233	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000217	0.00232	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000211	0.00226	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000202	0.00217	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000202	0.00217	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000199	0.00213	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000188	0.00202	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000185	0.00198	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00018	0.00193	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00018	0.00193	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000179	0.00192	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000179	0.00192	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000179	0.00192	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000179	0.00192	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000175	0.00188	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000174	0.00186	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000169	0.00182	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000166	0.00178	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000165	0.00177	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00016	0.00171	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000159	0.0017	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—DAO—amyotrophic lateral sclerosis	0.000157	0.00169	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000156	0.00167	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000153	0.00164	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000148	0.00158	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000146	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000145	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000145	0.00156	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000144	0.00154	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000143	0.00153	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000141	0.00151	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000139	0.00149	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000133	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—AMPK Signaling—TP53—amyotrophic lateral sclerosis	0.000131	0.0014	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000127	0.00136	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000126	0.00135	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000125	0.00134	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000125	0.00134	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000124	0.00133	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000124	0.00132	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000123	0.00131	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000122	0.00131	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.00012	0.00129	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000119	0.00128	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000116	0.00124	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000114	0.00122	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000111	0.00119	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSR—amyotrophic lateral sclerosis	0.00011	0.00118	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000107	0.00115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—DAO—amyotrophic lateral sclerosis	0.000105	0.00113	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000105	0.00112	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000103	0.00111	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000103	0.0011	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000101	0.00108	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	9.87e-05	0.00106	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	9.85e-05	0.00106	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	9.69e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	9.66e-05	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	9.54e-05	0.00102	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	9.45e-05	0.00101	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	9.4e-05	0.00101	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	9.26e-05	0.000992	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	9.19e-05	0.000985	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CHAT—amyotrophic lateral sclerosis	9.03e-05	0.000968	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.85e-05	0.000949	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	8.78e-05	0.000941	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.66e-05	0.000928	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	8.54e-05	0.000915	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	8.5e-05	0.000911	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.33e-05	0.000892	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—SOD1—amyotrophic lateral sclerosis	8.19e-05	0.000878	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.14e-05	0.000873	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	8.02e-05	0.00086	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	8.02e-05	0.00086	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PLB1—amyotrophic lateral sclerosis	7.96e-05	0.000853	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.89e-05	0.000846	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	7.82e-05	0.000838	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.72e-05	0.000827	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.64e-05	0.000819	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	7.64e-05	0.000818	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.55e-05	0.000809	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.48e-05	0.000802	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.48e-05	0.000801	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	7.46e-05	0.0008	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	7.35e-05	0.000788	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSR—amyotrophic lateral sclerosis	7.35e-05	0.000787	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	7.34e-05	0.000786	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	7.26e-05	0.000779	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.16e-05	0.000768	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.82e-05	0.000731	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.79e-05	0.000727	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.74e-05	0.000722	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.71e-05	0.000719	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	6.66e-05	0.000713	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.64e-05	0.000712	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.56e-05	0.000704	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	6.41e-05	0.000687	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.39e-05	0.000684	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	6.33e-05	0.000679	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.26e-05	0.000671	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	6.24e-05	0.000669	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.18e-05	0.000663	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	6.07e-05	0.000651	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CHAT—amyotrophic lateral sclerosis	6.03e-05	0.000647	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.93e-05	0.000636	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	5.8e-05	0.000622	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	5.75e-05	0.000616	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.61e-05	0.000601	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5.52e-05	0.000591	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.49e-05	0.000589	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.49e-05	0.000588	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.46e-05	0.000585	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.43e-05	0.000582	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.34e-05	0.000572	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.13e-05	0.00055	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.1e-05	0.000547	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.04e-05	0.000541	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IGF1—amyotrophic lateral sclerosis	5e-05	0.000536	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.96e-05	0.000531	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.85e-05	0.00052	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.85e-05	0.00052	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.81e-05	0.000516	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.61e-05	0.000494	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.58e-05	0.000491	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.54e-05	0.000487	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.51e-05	0.000483	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.46e-05	0.000478	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.42e-05	0.000474	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	4.39e-05	0.000471	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.32e-05	0.000463	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.23e-05	0.000453	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.22e-05	0.000452	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.12e-05	0.000441	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.1e-05	0.00044	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	4.06e-05	0.000435	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.03e-05	0.000432	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.01e-05	0.00043	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.92e-05	0.00042	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.73e-05	0.0004	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.73e-05	0.0004	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.69e-05	0.000396	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.69e-05	0.000395	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—APOE—amyotrophic lateral sclerosis	3.67e-05	0.000393	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.53e-05	0.000378	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.5e-05	0.000375	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.47e-05	0.000372	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.45e-05	0.00037	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.33e-05	0.000357	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	3.33e-05	0.000357	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.31e-05	0.000355	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	3.26e-05	0.00035	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.26e-05	0.000349	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.25e-05	0.000348	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.24e-05	0.000348	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.24e-05	0.000347	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.1e-05	0.000332	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.04e-05	0.000326	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.03e-05	0.000325	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.98e-05	0.000319	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.93e-05	0.000314	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.87e-05	0.000307	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.85e-05	0.000306	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.73e-05	0.000292	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.68e-05	0.000287	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.67e-05	0.000286	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.65e-05	0.000284	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.51e-05	0.000269	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.51e-05	0.000269	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.49e-05	0.000267	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—amyotrophic lateral sclerosis	2.47e-05	0.000264	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—amyotrophic lateral sclerosis	2.45e-05	0.000263	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.37e-05	0.000254	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.25e-05	0.000242	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.21e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.2e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.2e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.08e-05	0.000223	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.05e-05	0.00022	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.93e-05	0.000207	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.82e-05	0.000195	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.82e-05	0.000195	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.79e-05	0.000192	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.73e-05	0.000186	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.7e-05	0.000182	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.69e-05	0.000182	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.68e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.64e-05	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.64e-05	0.000176	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.64e-05	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.6e-05	0.000172	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.47e-05	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.44e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.4e-05	0.00015	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.35e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.33e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.3e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.24e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.23e-05	0.000132	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.19e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.11e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.11e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.09e-05	0.000117	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.27e-06	9.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9e-06	9.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.36e-06	8.96e-05	CbGpPWpGaD
